Sign Out
Probenecid: Decreased renal tubular secretion of DORIO; increased plasma concentrations, increased AUC and prolonged half-life of DORIO. Concomitant use not recommended.
Valproic acid: DORIO may inhibit valproic acid glucoronide hydrolysis and reduce serum valproic acid concentrations to subtherapeutic levels, resulting in loss of seizure control. Monitor serum valproic acid levels frequency after initiating DORIO therapy. Consider alternative anti-infective or anticonvulsant therapy if therapeutic serum valproic acid concentrations cannot be maintained or seizures occur.
